Cargando…

ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy

Physical plasmas generate unique mixes of reactive oxygen and nitrogen species (RONS or ROS). Only a bit more than a decade ago, these plasmas, operating at body temperature, started to be considered for medical therapy with considerably little mechanistic redox chemistry or biomedical research exis...

Descripción completa

Detalles Bibliográficos
Autores principales: Privat-Maldonado, Angela, Schmidt, Anke, Lin, Abraham, Weltmann, Klaus-Dieter, Wende, Kristian, Bogaerts, Annemie, Bekeschus, Sander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800937/
https://www.ncbi.nlm.nih.gov/pubmed/31687089
http://dx.doi.org/10.1155/2019/9062098
_version_ 1783460501136605184
author Privat-Maldonado, Angela
Schmidt, Anke
Lin, Abraham
Weltmann, Klaus-Dieter
Wende, Kristian
Bogaerts, Annemie
Bekeschus, Sander
author_facet Privat-Maldonado, Angela
Schmidt, Anke
Lin, Abraham
Weltmann, Klaus-Dieter
Wende, Kristian
Bogaerts, Annemie
Bekeschus, Sander
author_sort Privat-Maldonado, Angela
collection PubMed
description Physical plasmas generate unique mixes of reactive oxygen and nitrogen species (RONS or ROS). Only a bit more than a decade ago, these plasmas, operating at body temperature, started to be considered for medical therapy with considerably little mechanistic redox chemistry or biomedical research existing on that topic at that time. Today, a vast body of evidence is available on physical plasma-derived ROS, from their spatiotemporal resolution in the plasma gas phase to sophisticated chemical and biochemical analysis of these species once dissolved in liquids. Data from in silico analysis dissected potential reaction pathways of plasma-derived reactive species with biological membranes, and in vitro and in vivo experiments in cell and animal disease models identified molecular mechanisms and potential therapeutic benefits of physical plasmas. In 2013, the first medical plasma systems entered the European market as class IIa devices and have proven to be a valuable resource in dermatology, especially for supporting the healing of chronic wounds. The first results in cancer patients treated with plasma are promising, too. Due to the many potentials of this blooming new field ahead, there is a need to highlight the main concepts distilled from plasma research in chemistry and biology that serve as a mechanistic link between plasma physics (how and which plasma-derived ROS are produced) and therapy (what is the medical benefit). This inevitably puts cellular membranes in focus, as these are the natural interphase between ROS produced by plasmas and translation of their chemical reactivity into distinct biological responses.
format Online
Article
Text
id pubmed-6800937
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68009372019-11-04 ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy Privat-Maldonado, Angela Schmidt, Anke Lin, Abraham Weltmann, Klaus-Dieter Wende, Kristian Bogaerts, Annemie Bekeschus, Sander Oxid Med Cell Longev Review Article Physical plasmas generate unique mixes of reactive oxygen and nitrogen species (RONS or ROS). Only a bit more than a decade ago, these plasmas, operating at body temperature, started to be considered for medical therapy with considerably little mechanistic redox chemistry or biomedical research existing on that topic at that time. Today, a vast body of evidence is available on physical plasma-derived ROS, from their spatiotemporal resolution in the plasma gas phase to sophisticated chemical and biochemical analysis of these species once dissolved in liquids. Data from in silico analysis dissected potential reaction pathways of plasma-derived reactive species with biological membranes, and in vitro and in vivo experiments in cell and animal disease models identified molecular mechanisms and potential therapeutic benefits of physical plasmas. In 2013, the first medical plasma systems entered the European market as class IIa devices and have proven to be a valuable resource in dermatology, especially for supporting the healing of chronic wounds. The first results in cancer patients treated with plasma are promising, too. Due to the many potentials of this blooming new field ahead, there is a need to highlight the main concepts distilled from plasma research in chemistry and biology that serve as a mechanistic link between plasma physics (how and which plasma-derived ROS are produced) and therapy (what is the medical benefit). This inevitably puts cellular membranes in focus, as these are the natural interphase between ROS produced by plasmas and translation of their chemical reactivity into distinct biological responses. Hindawi 2019-10-08 /pmc/articles/PMC6800937/ /pubmed/31687089 http://dx.doi.org/10.1155/2019/9062098 Text en Copyright © 2019 Angela Privat-Maldonado et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Privat-Maldonado, Angela
Schmidt, Anke
Lin, Abraham
Weltmann, Klaus-Dieter
Wende, Kristian
Bogaerts, Annemie
Bekeschus, Sander
ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
title ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
title_full ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
title_fullStr ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
title_full_unstemmed ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
title_short ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy
title_sort ros from physical plasmas: redox chemistry for biomedical therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800937/
https://www.ncbi.nlm.nih.gov/pubmed/31687089
http://dx.doi.org/10.1155/2019/9062098
work_keys_str_mv AT privatmaldonadoangela rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy
AT schmidtanke rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy
AT linabraham rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy
AT weltmannklausdieter rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy
AT wendekristian rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy
AT bogaertsannemie rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy
AT bekeschussander rosfromphysicalplasmasredoxchemistryforbiomedicaltherapy